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Critically ill patients are at high risk of venous throm-
boembolism (VTE). However, the disease is often clini-
cally silent, especially in these patients, and is not asso-
ciated with any specific clinical sign or biologic mark-
er. It is, therefore, particularly difficult to diagnose this
condition in the ICU. D-dimers (DD) are cross-linked
fibrin derivatives that are produced upon fibrin degrada-
tion by plasmin. The DD concentration rises in various
conditions in which coagulation and fibrinolysis are ac-
tivated, e.g. in patients with VTE, but also in patients with
cancer, myocardial infarction, infectious or inflammato-
ry diseases, pregnancy and in the postoperative period.
Practically, patients with acute VTE are very likely to
present with an elevated DD level, corresponding to a
very high sensitivity to VTE, which in turn results in a
high negative predictive value. On the other hand, as DD
rise in various pathologic conditions [1], the proportion of
patients with increased DD may be substantial in patients
without VTE: the specificity (proportion of patients with
negative D-dimer test among those without VTE) of DD
testing is low, resulting in a poor positive predictive value
(PPV, proportion of patients with VTE among those with
positive D-dimer tests).
Although available DD assays are heterogeneous, a
negative result usually allows the exclusion of acute VTE:
in low clinical probability patients only for whole blood
agglutination assays [2] or even in all non-high clinical
probability patients for the most sensitive tests (ELISA or
immunoturbidimetric assays) [3, 4]. Hence, DD testing is
widely used as a first-line test, at least in outpatients with
suspected VTE, as VTE can be ruled out in about 30% of
such patients without further invasive and/or expensive
testing.
In this issue, Crowther et al. [5] report on a study using
six different commercial DD assays in a prospective co-
hort of 197 critically ill medical-surgical patients. The test
was performed upon admission to the ICU, and twice
weekly during the ICU stay. Bilateral compression ul-
trasonography of the lower limbs was performed at the
same time points, as well as at the time of any suspicion
of VTE. All patients had some kind of thrombo-prophy-
laxis during their ICU stays. The results confirm the fact
that DD testing is not useful for ruling out VTE in this
setting. Indeed, the proportion of patients with low DD
concentration decreases—and so does the clinical utility
of this test—in cancer patients, older subjects [6], inpa-
tients [7] or pregnant women [8]. Among the medical-
surgical critically ill patients included in the study by
Crowther et al., only 3.6% had negative bedside D-dimer
tests (thereby ruling out VTE), which definitely precludes
the use of these tests in ICU patients. This proportion was
higher (15.9%) in a previous study in ICU, but that study
included younger (62 vs 67 years) and less severely ill
patients (APACHE II 20.2 vs 25.7) [9].
The results also indicate that DD testing is not able to
identify correctly the ICU patients who have VTE. Ad-
mittedly, the areas under the ROC curve differ signifi-
cantly from 0.5 (which indicates that these tests have a
significant capacity to discriminate patients with and
without the disease), but these curves show that DD
testing reaches sufficient specificity to identify patients
with VTE only for very high DD levels, that very few
patients have. This observation is not surprising since the
specificity of DD is known to be not high enough—about
40% at a 500 mg/l threshold and above 93% only for
values above 4,000 mg/l when assayed by ELISA [10]—to
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ensure a clinically interesting PPV. This is even more true
when the prevalence of the disease is low. The prevalence
was only 5/197 (2.5%) upon ICU admission in the present
study. Consequently, specificity should have been par-
ticularly high to allow correct identification of the cases
by a positive test.
The authors have also evaluated the capacity of four
hypercoagulability tests (protein C, protein S, activated
protein C resistance ratio and antithrombin) and of D-
dimer to predict the occurrence of VTE during a mean
ICU stay of 12 days, as recently suggested by two groups
[11, 12]. Eventually, they found that none of these tests
was able to predict VTE occurrence, as demonstrated by
areas under the ROC curves that were not significantly
different from 0.5.
Although this is an original result, it could have been
anticipated, especially for DD testing [13]. Indeed, if DD
levels are highly sensitive to the presence of a clot and
even of a hypercoagulable state, as already said, their
specificity for the diagnosis of VTE in patients suspected
of having this is poor. Moreover, because of the low in-
cidence—here 11.6% over 12 days, mostly asymptom-
atic—a high PPV was not to be expected.
In conclusion, thanks to its high sensitivity for the
presence of VTE, DD testing allows, with some certainty,
the exclusion of the disease when negative (i.e. when the
concentration is below a validated diagnostic threshold) in
patients who are suspected of having it, if those patients
have (1) a low clinical probability when whole blood
agglutination assays are used or (2) a low or intermediate
clinical probability when highly sensitive tests such as
ELISA or some immunoturbidimetric assays are used.
Due to its poor specificity and to the relatively low
prevalence of the disease in patients suspected of having
it, DD testing can not be used to establish the diagnosis in
these patients nor to predict VTE occurrence in at-risk
patients. Moreover, because they have only little chance
of being negative in critically ill patients, the use of these
tests should be discouraged in such patients. New biologic
tests must be applied for validated indications in appro-
priate patient populations. All divergent uses are likely to
result in financial losses and, more importantly, in clini-
cally useless or even misleading information.
